<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04005482</url>
  </required_header>
  <id_info>
    <org_study_id>MUVienna 1568/2014</org_study_id>
    <nct_id>NCT04005482</nct_id>
  </id_info>
  <brief_title>Blood Pressure During Rate Control in Patients With Tachycardic Atrial Fibrillation at the Emergency Department</brief_title>
  <acronym>BPIRCTPTAF</acronym>
  <official_title>Blood Pressure During Rate Control in Patients With Tachycardic Atrial Fibrillation at the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to analyse blood pressure during rate control therapy in patients
      with tachycardic atrial fibrillation in a real-world emergency cohort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is the primary clinical problem in 3.3% to 10.0 % emergency
      department (ED) admissions. Rate control is an integral part of the management of symptomatic
      tachycardic AF patients.

      According to the recent guidelines beta-blockers, digoxin, the calcium channel blockers
      diltiazem and verapamil, amiodarone or combination therapy should be considered for rate
      control. Haemodynamic side-effects in particular hypotension may occur. Heart rate and blood
      pressure behavior in an ED population during rate control therapy in patients with
      tachycardic atrial fibrillation will be analysed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2019</start_date>
  <completion_date type="Anticipated">July 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean and maximum blood pressure difference between before (baseline) and during/after medication.</measure>
    <time_frame>20th July 2019 to 20th July 2021</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rate control</intervention_name>
    <description>Rate control according to the Atrial fibrillation - ESC Guidelines 2016</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We plan to include all patients admitted to the Emergency Department of the Medical
        University Vienna with tachycardic AF receiving rate control therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Atrial fibrillation or atrial flutter and heart rate ≥ 110 bpm

          -  Indication for rate control

          -  Informed consent

        Exclusion Criteria:

        • Inclusion criteria not met
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Domanovits, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Emergency Department, Medical University Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Niederdöckl, Dr.med.univ</last_name>
    <phone>0043 40400 19640</phone>
    <email>jan.niederdoeckl@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Filippo Cacioppo</last_name>
    <phone>0043 40400 19640</phone>
    <email>filippo.cacioppo@meduniwien.ac.at</email>
  </overall_contact_backup>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Hans Domanovits</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

